Discontinue use if anaphylactic reactions develop & angioedema occurs. Clinically significant bladder outflow obstruction at risk of urinary retention; GI obstructive disorders; risk of decreased GI motility; hiatus hernia/GERD; autonomic neuropathy. Patients w/ neurogenic cause for detrusor overactivity; known risk factors for QT prolongation ie, history of QT prolongation, long QT syndrome, hypokalaemia, bradycardia; relevant pre-existing cardiac diseases ie, myocardial ischaemia, arrhythmia, CHF. May cause serious allergic-type reactions due to Na metabisulfite. Concomitant use w/ potent CYP3A4 inhibitor eg, ketoconazole; medicinal products causing or exacerbating oesophagitis eg, bisphosphonates. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Severe renal (CrCl ≤30 mL/min) & moderate hepatic (Child-Pugh score 7-9) impairment. Pregnancy. Avoid use during lactation. Not to be used in childn.